Literature DB >> 22132837

Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center.

Paolo Anderlini, Rima Saliba, Sandra Acholonu, Grace-Julia Okoroji, Celina Ledesma, Borje S Andersson, Roy Jones, Uday R Popat, Chitra M Hosing, Yago Nieto, Muzaffar H Qazilbash, Naoto T Ueno, Sergio A Giralt, Marcos J de Lima, Richard E Champlin.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22132837      PMCID： PMC4493857          DOI： 10.3109/10428194.2011.644547

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  10 in total

1.  Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation.

Authors:  Karl S Peggs; Ann Hunter; Rajesh Chopra; Anne Parker; Premini Mahendra; Donald Milligan; Charles Craddock; Ruth Pettengell; Ahmet Dogan; Kirsty J Thomson; Emma C Morris; Geoff Hale; Herman Waldmann; Anthony H Goldstone; David C Linch; Stephen Mackinnon
Journal:  Lancet       Date:  2005 Jun 4-10       Impact factor: 79.321

2.  Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma.

Authors:  Karl S Peggs; Irfan Kayani; Noha Edwards; Panagiotis Kottaridis; Anthony H Goldstone; David C Linch; Rachael Hough; Emma C Morris; Adele Fielding; Ronjon Chakraverty; Kirsty J Thomson; Stephen Mackinnon
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

Review 3.  Allogeneic transplantation for Hodgkin lymphoma.

Authors:  Karl S Peggs; Paolo Anderlini; Anna Sureda
Journal:  Br J Haematol       Date:  2008-08-15       Impact factor: 6.998

4.  Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

Authors:  Anas Younes; Nancy L Bartlett; John P Leonard; Dana A Kennedy; Carmel M Lynch; Eric L Sievers; Andres Forero-Torres
Journal:  N Engl J Med       Date:  2010-11-04       Impact factor: 91.245

5.  Demonstration of durable graft versus lymphoma effects in Hodgkin's lymphoma.

Authors:  Paul J Greaves; John G Gribben
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

Review 6.  'GVHD': graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning.

Authors:  D L Porter; E A Stadtmauer; H M Lazarus
Journal:  Bone Marrow Transplant       Date:  2003-05       Impact factor: 5.483

7.  Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response.

Authors:  P Anderlini; S A Acholonu; G-J Okoroji; B S Andersson; D R Couriel; M J De Lima; M L Donato; I F Khouri; S A Giralt; N T Ueno; R E Champlin
Journal:  Bone Marrow Transplant       Date:  2004-09       Impact factor: 5.483

8.  Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.

Authors:  Karl S Peggs; Anna Sureda; Wendi Qian; Dolores Caballero; Ann Hunter; Alvaro Urbano-Ispizua; James Cavet; Josep M Ribera; Anne Parker; Miguel Canales; Premini Mahendra; Javier Garcia-Conde; Donald Milligan; Guillermo Sanz; Kirsty Thomson; Reyes Arranz; Anthony H Goldstone; Ivan Alvarez; David C Linch; Jorge Sierra; Stephen Mackinnon
Journal:  Br J Haematol       Date:  2007-10       Impact factor: 6.998

9.  Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.

Authors:  Paolo Anderlini; Rima Saliba; Sandra Acholonu; Sergio A Giralt; Borje Andersson; Naoto T Ueno; Chitra Hosing; Issa F Khouri; Daniel Couriel; Marcos de Lima; Muzaffar H Qazilbash; Barbara Pro; Jorge Romaguera; Luis Fayad; Frederick Hagemeister; Anas Younes; Mark F Munsell; Richard E Champlin
Journal:  Haematologica       Date:  2008-01-26       Impact factor: 9.941

10.  Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome.

Authors:  Stephen P Robinson; Anna Sureda; Carmen Canals; Nigel Russell; Dolores Caballero; Andrea Bacigalupo; Arturo Iriondo; Gordon Cook; Andrew Pettitt; Gerard Socie; Francesca Bonifazi; Alberto Bosi; Mauricette Michallet; Effie Liakopoulou; Johan Maertens; Jakob Passweg; Fiona Clarke; Rodrigo Martino; Norbert Schmitz
Journal:  Haematologica       Date:  2008-12-09       Impact factor: 9.941
  10 in total
  4 in total

Review 1.  Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!

Authors:  M A Kharfan-Dabaja; M Hamadani; H Sibai; B N Savani
Journal:  Bone Marrow Transplant       Date:  2014-01-20       Impact factor: 5.483

2.  Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation.

Authors:  P Tsirigotis; I Danylesko; K Gkirkas; N Shem-Tov; R Yerushalmi; M Stamouli; A Avigdor; A Spyridonidis; J Gauthier; G Goldstein; J Apostolidis; M Mohty; A Shimoni; A Nagler
Journal:  Bone Marrow Transplant       Date:  2016-05-16       Impact factor: 5.483

Review 3.  Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma.

Authors:  Michael D Jain; John Kuruvilla
Journal:  Drugs       Date:  2017-10       Impact factor: 11.431

4.  Relapsing/refractory HL after autotransplantation: which treatment?

Authors:  Nicola Di Renzo; Francesco Gaudio; Carmelo Carlo Stella; Sara Oppi; Matteo Pelosini; Roberto Sorasio; Caterina Stelitano; Luigi Rigacci
Journal:  Acta Biomed       Date:  2020-05-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.